These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Stricter cholesterol guidelines broaden indications for the 'statin' drugs. Capriotti T Medsurg Nurs; 2003 Feb; 12(1):51-7. PubMed ID: 12619600 [No Abstract] [Full Text] [Related]
6. An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels. Rhainds D; Arsenault BJ; Brodeur MR; Tardif JC Future Cardiol; 2012 Jul; 8(4):513-31. PubMed ID: 22871191 [TBL] [Abstract][Full Text] [Related]
7. Residual risk and high-density lipoprotein cholesterol levels: is there a relationship? Shah PK Rev Cardiovasc Med; 2011; 12(2):e55-9. PubMed ID: 21796083 [TBL] [Abstract][Full Text] [Related]
8. The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors. Vergeer M; Stroes ES Am J Cardiol; 2009 Nov; 104(10 Suppl):32E-8E. PubMed ID: 19895942 [TBL] [Abstract][Full Text] [Related]
9. When good cholesterol turns bad: the evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein. Oram JF; Heinecke JW Curr Atheroscler Rep; 2007 Dec; 9(6):425-7. PubMed ID: 18377780 [No Abstract] [Full Text] [Related]
10. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents. Shinkai H Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630 [TBL] [Abstract][Full Text] [Related]
11. Should every patient with diabetes receive a statin? Dembowski E; Davidson MH Pol Arch Med Wewn; 2008; 118(7-8):398-401. PubMed ID: 18714733 [No Abstract] [Full Text] [Related]
12. Current status of CETP inhibitors in the treatment of hyperlipidemia: an update. Ghosh RK; Ghosh SM Curr Clin Pharmacol; 2012 May; 7(2):102-10. PubMed ID: 22432840 [TBL] [Abstract][Full Text] [Related]
13. CardioPulse: is raising HDL a valid treatment target? : epidemiological studies show a relationship between high HDL and lower cardiovascular events but subsequent research casts doubt on treatment benefit. Taylor J Eur Heart J; 2013 Apr; 34(16):1174. PubMed ID: 23604754 [No Abstract] [Full Text] [Related]
14. [HDL and CETP in atherogenesis]. Pöss J; Böhm M; Laufs U Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258 [TBL] [Abstract][Full Text] [Related]
15. Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors? Miura S; Saku K J Hypertens; 2010 Aug; 28(8):1614-6. PubMed ID: 20647856 [No Abstract] [Full Text] [Related]
17. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism. Niesor EJ Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074 [TBL] [Abstract][Full Text] [Related]
18. Shedding light on high-density lipoprotein cholesterol: the post-ILLUMINATE era. Lavie CJ; Milani RV J Am Coll Cardiol; 2008 Jan; 51(1):56-8. PubMed ID: 18174037 [No Abstract] [Full Text] [Related]
19. Treating high-density lipoprotein cholesterol: a return to inhibition of cholesteryl ester transfer protein? Duriez P Curr Atheroscler Rep; 2008 Jun; 10(3):177-9. PubMed ID: 18489843 [No Abstract] [Full Text] [Related]
20. [Strengthened support for statin therapy as secondary prevention. Doubtful evidence for more intensive lowering of cholesterol levels]. Håkansson J Lakartidningen; 2011 Jun 1-14; 108(22-23):1234-5. PubMed ID: 21786497 [No Abstract] [Full Text] [Related] [Next] [New Search]